Hemgenix
Hemgenix
Product Specs | Hemgenix |
---|---|
Manufacturer Name | CSL Behring |
Indications | HEMGENIX is an adeno-associated virus vector-based gene therapy indicated for treatment of adults with Hemophilia B (congenital Factor IX deficiency) who:
|
Contraindications | None known |
Viral Safety Process | HEMGENIX (etranacogene dezaparvovec-drlb) is an adeno-associated viral vector-based gene therapy for intravenous infusion after dilution. HEMGENIX is a non-replicating recombinant AAV5 containing a codon-optimized DNA sequence of the gain-of-function Padua variant of human Factor IX (variant R338L), under control of a liver-specific promotor 1 (LP1). |
Product Half-Life | Factor IX activity levels of 39% (± 18.7), 41.5% (± 21.7), 36.9% (± 606 21.4) and 36.7 (± 19.0) of normal, respectively, at 6, 12, 18 and 24 months. |
Manufacturing Method | |
Storage Requirements | Before Dilution
After Dilution |
Shelf Life | Label lists the expiration date/time (24 h from the vial removal from refrigerator) |
Nominal Vial Size & Diluent Volume | 1 x 1013 gc/mL, and each vial contains an extractable volume of not less than 10 mL Patient body weight is less than 120 kg: Patient body weight is greater than or equal to 120 kg: |
Route of Administration | Intravenous Administration |
Return to Manufacturer Name listing Return to Factor Type listing